These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 33011088)

  • 1. Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis.
    Pan L; Huang P; Xie X; Xu J; Guo D; Jiang Y
    Dig Liver Dis; 2021 Feb; 53(2):153-157. PubMed ID: 33011088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Severe COVID-19 Increased by Metabolic Dysfunction-associated Fatty Liver Disease: A Meta-analysis.
    Tao Z; Li Y; Cheng B; Zhou T; Gao Y
    J Clin Gastroenterol; 2021 Nov-Dec 01; 55(10):830-835. PubMed ID: 34406175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019.
    Gao F; Zheng KI; Yan HD; Sun QF; Pan KH; Wang TY; Chen YP; Targher G; Byrne CD; George J; Zheng MH
    Front Endocrinol (Lausanne); 2021; 12():604100. PubMed ID: 33763027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis.
    Hayat U; Ashfaq MZ; Johnson L; Ford R; Wuthnow C; Kadado K; El Jurdi K; Okut H; Kilgore WR; Assi M; Siddiqui AA
    Kans J Med; 2022; 15():241-246. PubMed ID: 35899064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19.
    Sharma P; Kumar A
    Diabetes Metab Syndr; 2020; 14(5):825-827. PubMed ID: 32540736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management.
    Xu Y; Yang X; Bian H; Xia M
    Lipids Health Dis; 2021 Oct; 20(1):126. PubMed ID: 34602072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis.
    Hegyi PJ; Váncsa S; Ocskay K; Dembrovszky F; Kiss S; Farkas N; Erőss B; Szakács Z; Hegyi P; Pár G
    Front Med (Lausanne); 2021; 8():626425. PubMed ID: 33777974
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients.
    Gao F; Zheng KI; Wang XB; Yan HD; Sun QF; Pan KH; Wang TY; Chen YP; George J; Zheng MH
    J Gastroenterol Hepatol; 2021 Jan; 36(1):204-207. PubMed ID: 32436622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic-associated fatty liver disease is associated with severity of COVID-19.
    Zhou YJ; Zheng KI; Wang XB; Sun QF; Pan KH; Wang TY; Ma HL; Chen YP; George J; Zheng MH
    Liver Int; 2020 Sep; 40(9):2160-2163. PubMed ID: 32573883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight.
    Vasques-Monteiro IML; Souza-Mello V
    World J Gastroenterol; 2021 Apr; 27(16):1738-1750. PubMed ID: 33967554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease.
    Jeeyavudeen MS; Chaudhari R; Pappachan JM; Fouda S
    World J Gastroenterol; 2023 Jan; 29(3):487-502. PubMed ID: 36688018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAFLD in COVID-19 patients: an insidious enemy.
    Dongiovanni P; Meroni M; Longo M; Fracanzani AL
    Expert Rev Gastroenterol Hepatol; 2020 Oct; 14(10):867-872. PubMed ID: 32705906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19.
    Campos-Murguía A; Román-Calleja BM; Toledo-Coronado IV; González-Regueiro JA; Solís-Ortega AA; Kúsulas-Delint D; Cruz-Contreras M; Cruz-Yedra N; Cubero FJ; Nevzorova YA; Martínez-Cabrera CF; Moreno-Guillén P; Lozano-Cruz OA; Chapa-Ibargüengoitia M; Gulías-Herrero A; Aguilar-Salinas CA; Ruiz-Margáin A; Macías-Rodríguez RU
    Dig Liver Dis; 2021 May; 53(5):525-533. PubMed ID: 33551355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity.
    Lamadrid P; Alonso-Peña M; San Segundo D; Arias-Loste M; Crespo J; Lopez-Hoyos M
    Front Immunol; 2021; 12():651728. PubMed ID: 33859644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic performance of an index based on lactic dehydrogenase and transaminases for patients with liver steatosis and COVID-19.
    Macías-Rodríguez RU; Solís-Ortega AA; Ornelas-Arroyo VJ; Ruiz-Margáin A; González-Huezo MS; Urdiales-Morán NA; Román-Calleja BM; Mayorquín-Aguilar JM; González-Regueiro JA; Campos-Murguía A; Toledo-Coronado IV; Chapa-Ibargüengoitia M; Valencia-Peña B; Martínez-Cabrera CF; Flores-García NC
    World J Gastroenterol; 2022 Oct; 28(37):5444-5456. PubMed ID: 36312835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic associated fatty liver disease and adverse maternal and fetal outcomes: a systematic review and meta-analysis.
    Dyah AA; Rahadina R
    Clin Exp Hepatol; 2021 Sep; 7(3):305-311. PubMed ID: 34712833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD.
    Chen H; Chen Q
    Int J Biol Sci; 2022; 18(12):4756-4767. PubMed ID: 35874945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19.
    Campos-Murguía A; Román-Calleja BM; González-Regueiro JA; Hurtado-Díaz-de-León I; Solís-Ortega AA; Flores-García NC; García-Juárez I; Ruiz-Margáin A; Macías-Rodríguez RU
    World J Gastroenterol; 2021 Sep; 27(33):5502-5519. PubMed ID: 34588748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of circulating omentin level and metabolic-associated fatty liver disease: a systematic review and meta-analysis.
    Zhang Q; Chen S; Ke Y; Li Q; Shen C; Ruan Y; Wu K; Hu J; Liu S
    Front Endocrinol (Lausanne); 2023; 14():1073498. PubMed ID: 37139340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals.
    Chan KE; Koh TJL; Tang ASP; Quek J; Yong JN; Tay P; Tan DJH; Lim WH; Lin SY; Huang D; Chan M; Khoo CM; Chew NWS; Kaewdech A; Chamroonkul N; Dan YY; Noureddin M; Muthiah M; Eslam M; Ng CH
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2691-2700. PubMed ID: 35587339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.